IBSA Group

Pharmaceutical Manufacturing • Montagnola, Ticino, Switzerland • 1001-2000 Employees

Company overview

Headquarters	Via del Piano 29, Lugano, Svizzera CH-6915, CH
Phone number	+41583601000
Website	ibsagroup.com
NAICS	3254
SIC	283
Keywords	Pharmaceutical, R&D, Rheumatology, Pain, Endocrinology, Dermatology, Fertility, Pharma Industry, Cardiovascular, Drugs, Urology, Inflammation, Human Reproduction, Respiratory, Dermoaesthetic
Employees	1001-2000
Socials

Key Contact at IBSA Group

Jens Schultka

Head of Sales

Mobile @ibsagroup.com

IBSA Group Email Formats

IBSA Group uses 5 email formats. The most common is {first name}.{last name} (e.g., john.doe@ibsagroup.com), used 57.9% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@ibsagroup.com	64.8%
{first initial}.{last name}	j.doe@ibsa.ch	31.9%

About IBSA Group

IBSA Institut Biochimique SA is a privately owned pharmaceutical company founded in Lugano in 1945. It started to develop its specific identity in 1985, when the current management took over, redefining its strategy and focusing on developing technologies that improve the quality of existing therapeutic solutions. Today, it is present on 5 continents and over 90 countries. The Group now counts on 20 subsidiaries in Europe, China and USA, and boasts a product portfolio covering 10 therapeutic areas. The company employs over 2,300 people, distributed among its headquarters, subsidiaries and manufacturing sites. IBSA is one of the four largest operators worldwide in the area of Reproductive Medicine and one of the world's leaders in hyaluronic acid-based products. Therapeutic areas: 🔹 Reproductive Medicine 🔹 Endocrinology 🔹 Pain and Inflammation 🔹 Osteoarticular 🔹 Aesthetic Medicine 🔹 Dermatology 🔹 Uro-gynaecology 🔹 Cardiometabolic 🔹 Respiratory 🔹 Consumer Health

IBSA Group revenue & valuation

Annual revenue	$540,100,000
Revenue per employee	$502,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$1,728,400,000
Total funding	No funding